Journal: Journal of Clinical and Translational Hepatology
Special Issue: Coronavirus Disease (COVID-19) and the Liver
Guest Editors: Dr. Cyriac Abby Philips, Dr. Tanmay Vyas, Dr. Ashwani K. Singal, Dr. Anand V. Kulkarni, Dr. Jawad Nazir
Status: Open
Submission deadline: June 30, 2021
Publication date: An article will be published online as soon as it is accepted
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), is now a global pandemic, but a huge knowledge gap remains about the effects of this novel virus on the human body. Because angiotensin-converting enzyme 2 (ACE2), the reported receptor for SARS-CoV-2, is highly expressed in almost the entire gastrointestinal tract, a significant portion of patients develop elevated liver enzyme levels and gastrointestinal symptoms, but the underlying pathophysiology is obscure.
For this special issue, we invite front-line hepatologists and liver researchers to submit high-quality scientific manuscripts regarding COVID-19. Potential topics include, but are not limited to:
- GI and liver manifestations of COVID-19
- Causes of liver injury in COVID-19
- Characteristic findings from liver function tests in COVID-19 patients
- Effects of COVID-19 treatments on the liver
- Interaction between existing liver disease and COVID-19
- Impact of new and future therapies for COVID-19 in persons with liver disease
- Evidence that COVID-19 causes direct liver injury (Narrative evidence-based debate)
- Evidence that COVID-19 does not cause direct liver injury (Narrative evidence-based debate)
- COVID-19 and liver: What all hepatologists must know
- The cytokine storm of COVID-19 and its impact in patients with and without liver disease
- Liver transplantation services during the time of COVID-19—work up, listing, pre- and post-op—has anything changed?
- A pictorial guide to performing diagnostic and endoscopic services for portal hypertensive complications in COVID-19 hot zones
- Evaluation and management of acute cellular rejection of graft liver in COVID-19—learning pearls from an epicenter
- Case-based approach to managing COVID-19 patients with liver disease resulting from COVID-19 versus an underlying liver disease
The authors should refer to the Instructions for Authors in preparing the manuscript and kindly submit it through the Online Submission System directly.
Priority will be given with the same high standards of peer review and publication process for these articles. To help fight the epidemic, authors publishing papers regarding COVID-19 will not be charged any fees, and all publications will open free access to all readers. We guarantee that all accepted papers related to COVID-19 will be highlighted in a special section on our website.
Guest Editors’ Profiles:
Cyriac Abby Philips, M.D., D.M.
Dr. Philips is the Clinical Lead of The Liver Unit, Cochin Gastroenterology Group, based in Kochi, and Director of the Monarch Liver Lab, Department of Clinical and Experimental Gastroenterology and Hepatology at the Ernakulam Medical Center Hospital, Kochi, Kerala, India. He is a two-time Clinical Hepatology plenary awardee (2015, 2017) of the American Association for Study of Liver Diseases (AASLD) and four-time AASLD and European Association for Study of Liver (EASL) Young Investigator Award winner (2015 (AASLD), 2016 (AASLD), 2017 (AASLD), 2017 (EASL)) and recipient of the prestigious President of India Excellence in Hepatology from Institute of Liver and Biliary Sciences, New Delhi in 2016. He has published over 140 peer-reviewed studies in high-impact journals including Gastroenterology, Hepatology, Journal of Hepatology, Clinical Gastroenterology and Hepatology, and the American Journal of Gastroenterology. His interests and expertise include study of the gut microbiome and its modulation in severe alcoholic hepatitis and sepsis, portosystemic shunt syndrome, drug-induced liver injury, especially Ayurvedic herbals, and infections in cirrhosis. His pioneering work in the field of liver diseases has included the introduction of healthy donor fecal transplantation for severe alcoholic hepatitis and novel data on clinical outcomes, toxicology, and chemical analysis of Ayurvedic herbal-induced liver injury for which he received the Indian National Award for Best Paper in 2019 from The Indian Society of Gastroenterology and SpringerNature.
.jpg)
Tanmay Vyas, M.D., D.M.
Dr. Vyas is Honorary Consultant Hepatologist at the Institute of Transplantation Sciences of the Institute of Kidney Diseases and Research Centre; and Consultant in the Department of Hepatology, Sterling Hospitals, both at Ahmedabad, Gujarat, India. He is a keen academician with high-impact publications and is the recipient of the Presidential Award for best paper at the Asian-Pacific Association for the Study of Liver (APASL) 2016. Also, he has won the Young Investigator Award of the American Association for Study of Liver Diseases (AASLD, 2016) and the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN, 2017) for his exemplary work on non-alcoholic fatty liver disease and hepatic encephalopathy respectively. His area of work and interest includes fatty liver disease, viral hepatitis, hepatic encephalopathy and antifibrotic therapy, and regression of cirrhosis.
Ashwani K. Singal, M.D., D.M.
Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine. In addition, he is also the Chief of Clinical Research Affairs at the Avera Transplant Institute.
With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institutes of Health, and pharmaceutical industry. He has published more than 180 original peer-reviewed articles in national/international journals as well as book chapters. He is on the editorial board of many journals including Liver Transplantation and Journal of Hepatology, also serving as co-editor-in-chief for Translational Gastroenterology Hepatology and associate editor for Digestive Liver Disease, PLOS One, and Journal of Clinical Translational Hepatology.
Apart from reviewing research grants and scientific research abstracts for the American Gastroenterology Association and the American Association for Study of Liver Diseases (AASLD), Dr. Singal serves on grant review study sections for the NIH. Dr. Singal was a lead author on the practice guidelines for alcoholic liver disease, has co-authored guidelines for vascular disorders of the liver, and is currently involved in writing guidelines for nutritional management of patients with cirrhosis. Dr. Singal has been awarded the prestigious Edgar Achkar Visiting Professorship by the ACG and also chairs the special interest group on alcohol-related liver disease of the AASLD.
Anand V. Kulkarni, M.D., D.M.
Dr. Anand V. Kulkarni is a Hepatologist working at the Asian Institute of Gastroenterology, Hyderabad, India. He earned his DM in Hepatology & Liver Transplantation from Asia’s premier center, the Institute of Liver and Biliary Sciences (ILBS), Delhi. He has several publications to his credit. He is also a reviewer and editorial member for many esteemed journals. He received the fellow research award from the esteemed AASLD (American Association for Study of Liver Disease’s) for the best abstract submitted at The Liver Meeting 2017. He received the academic excellence award in 2018 from the Institute of Liver and Biliary Sciences, New Delhi. He was also a recipient of the ICMR (Indian Council of Medical Research) and DBT (Department of Biotechnology) awards for paper presentation at AASLD 2016 and 2017, respectively. His primary focus of interest is portal hypertension and alcoholic liver disease.
Jawad Nazir, M.D., D.M.
Dr. Jawad Nazir is an experienced and well-respected ABIM board-certified infectious disease consultant at Avera McKennan Hospital and University Health Center.
Dr. Nazir graduated from King Edward Medical University, Lahore Pakistan in 1993 and completed internal medicine residency training at the University of Pittsburgh Medical Center McKeesport, Pennsylvania in 2001 followed by infectious disease fellowship training at New York Presbyterian Hospital Queens from 2001-2003. During his fellowship training, he had the opportunity to gain experience in managing hospitalized patients with SARS CoV-1, anthrax, and West Nile virus meningoencephalitis.
Apart from his busy clinical practice, he is a Clinical Professor of Medicine at the Sanford School of Medicine of the University of South Dakota. Dr. Nazir is also the Medical Director of infection prevention, control and antimicrobial stewardship for Avera McKennan Hospital and Avera Health and has successfully completed several quality improvement projects. His medical interests include infections in immunocompromised hosts, including solid organ transplant recipients, antimicrobial resistance, and telehealth, and he has published several peer-reviewed articles. Dr. Nazir is a fellow of the American College of Physicians and a member of several professional societies, including the Infectious Disease Society of America, the Society of Hospital Epidemiology and Infection Control, and the American Telemedicine Association.
Online submission system: https://www.editorialmanager.com/jcth/
Instructions for authors: Please state in a cover letter that the manuscript is being submitted for inclusion in the special issue ‘Coronavirus Disease (COVID-19) and the Liver’ and follow the usual JCTH instructions. Please refer to: https://www.xiahepublishing.com/journal/jcth/instruction
For any inquiries, please contact the journal by e-mail: jcth@xiahepublishing.com